A Safety and Efficacy Study of Hospitalized Patients With Community-Acquired Pneumonia and Sepsis

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Hospitalized Patients With Community-Acquired Pneumonia and Sepsis

The objective of this study is to demonstrate the safety and efficacy of IC14 in the treatment of hospitalized patients with community-acquired pneumonia and sepsis.

Inclusion Criteria:

• Current diagnosis of community-acquired pneumonia.
• Evidence of systemic inflammatory response to infection.

Exclusion Criteria:

• Atypical or viral pneumonia based on clinical or epidemiologic suspicion by the investigator.
• Presence of organ failure.